GHK-Cu for Dogs
Copper tripeptide (glycyl-L-histidyl-L-lysine copper)
The short answer
GHK-Cu used topically is among the lowest-risk options on this site — systemic absorption is minimal and long-term use is generally considered acceptable. Note that despite frequent claims otherwise, there is no canine study behind it: the often-cited Veterinary Surgery paper was conducted in rats. The injectable route carries a genuine, breed-specific hazard: Bedlington Terriers and some Labrador lines carry inherited copper storage disease, and any dog with hepatic impairment handles copper poorly. Baseline and follow-up liver values are the safeguard, and for localised problems the topical route usually makes the injectable question moot.
What it is and how it is thought to work
GHK-Cu is a three-amino-acid peptide bound to copper, found naturally in blood plasma at levels that decline with age. Research describes it influencing the expression of several thousand genes involved in tissue remodelling, which is why it appears in both wound-healing and skin and coat contexts. The wound-healing evidence is genuinely strong, but it is rodent and human — no canine study exists, despite the frequently cited paper having appeared in a veterinary journal.
Mechanism in clinical terms
Reported to up- and downregulate at least 4,000 human genes, with upregulation of collagen I and III, decorin, and glycosaminoglycan synthesis among the changes relevant to tissue remodelling. A study published in Veterinary Surgery evaluated topical tripeptide-copper complex on ischaemic open wounds, though it was conducted in rats rather than dogs.
Canine dosing by weight class
Figures below are reported as they appear in the source literature. They are not recommendations, and dosing for an individual dog must be set by a veterinarian.
Small / toy breed
under 22 lb (10 kg)
- Reported dose
- 0.5-1 mg per day injectable, or topical twice daily
- Frequency
- Daily (injectable) / twice daily (topical)
- Duration
- 4-8 weeks injectable, topical ongoing
- Studied for
- Wound healing, skin and coat, post-surgical incisions
Medium breed
22–77 lb (10–35 kg)
- Reported dose
- 1-1.5 mg per day injectable, or topical twice daily
- Frequency
- Daily (injectable) / twice daily (topical)
- Duration
- 4-8 weeks injectable, topical ongoing
- Studied for
- Wound healing, skin and coat, joint support
Large / giant breed
over 77 lb (35 kg)
- Reported dose
- 1.5-2 mg per day injectable, or topical twice daily
- Frequency
- Daily (injectable) / twice daily (topical)
- Duration
- 4-8 weeks injectable, topical ongoing
- Studied for
- Wound healing, post-surgical recovery, chronic dermatologic conditions
Need a figure for a specific weight? Use the dose calculator, or see the weight-specific pages: small / toy breed, medium breed, large / giant breed.
Contraindications and warnings
Read these before anything else on the page.
⚠ Copper storage disease in predisposed breeds
Bedlington Terriers and certain Labrador Retriever lines carry an inherited copper storage disorder. In these dogs the injectable route risks hepatic copper accumulation. Hepatic function must be monitored, and the topical route is strongly preferred.
Pre-existing hepatic disease
Any dog with known liver disease should avoid the injectable route. Copper handling is a hepatic function and impaired clearance changes the risk calculation entirely.
Example research protocol
A representative timeline drawn from the published literature, showing what is monitored and when. Any actual protocol should be set by the veterinarian managing the case.
- 1Days 1-7Initiation
What owners observe
For topical use, apply a thin layer to the affected area twice daily. Expect no visible change in the first week. Watch for any irritation at topical sites.
Clinical monitoring
Baseline liver values given copper metabolism. Collagen synthesis upregulation is reported to begin within 48-72 hours.
- 2Weeks 2-4Active remodelling
What owners observe
Wound closure visibly accelerating. Coat quality often improves as a secondary effect — thicker, glossier regrowth around treated areas. Surgical incisions healing faster than expected.
Clinical monitoring
Collagen I/III deposition and glycosaminoglycan synthesis elevated. Reassess the wound bed at week 3. Continue daily or reduce to three times weekly based on response.
- 3Weeks 4-8Taper to topical only
What owners observe
Meaningful wound healing or coat improvement should be evident. For chronic skin conditions, topical maintenance is often continued long term.
Clinical monitoring
Discontinue the injectable route after 4-8 weeks. Recheck liver values if injectable was used beyond 4 weeks. Topical carries no systemic copper accumulation concern at these doses.
What GHK-Cu is investigated for
Wound healing
Repair of surgical incisions, lacerations, ulcers, and chronic non-healing wounds.
Skin and coat
Coat quality, hair regrowth, and chronic dermatologic conditions.
Post-surgical recovery
Supporting tissue repair, comfort, and return to function after an orthopaedic or soft tissue procedure.
Osteoarthritis
Progressive cartilage loss and joint inflammation, affecting a large share of dogs over eight years old.
How it compares
- BPC-157 vs GHK-Cu for dogs — how GHK-Cu differs from BPC-157
- TB-500 vs GHK-Cu for dogs — how GHK-Cu differs from TB-500
Common questions
Is GHK-Cu safe for dogs?+
GHK-Cu used topically is among the lowest-risk options on this site — systemic absorption is minimal and long-term use is generally considered acceptable. Note that despite frequent claims otherwise, there is no canine study behind it: the often-cited Veterinary Surgery paper was conducted in rats. The injectable route carries a genuine, breed-specific hazard: Bedlington Terriers and some Labrador lines carry inherited copper storage disease, and any dog with hepatic impairment handles copper poorly. Baseline and follow-up liver values are the safeguard, and for localised problems the topical route usually makes the injectable question moot.
How much GHK-Cu should I give my dog?+
Reported doses vary by weight class. Small / toy breed (under 22 lb (10 kg)): 0.5-1 mg per day injectable, or topical twice daily, daily (injectable) / twice daily (topical). Medium breed (22–77 lb (10–35 kg)): 1-1.5 mg per day injectable, or topical twice daily, daily (injectable) / twice daily (topical). Large / giant breed (over 77 lb (35 kg)): 1.5-2 mg per day injectable, or topical twice daily, daily (injectable) / twice daily (topical). These figures are reported as they appear in the source literature and are not recommendations — dosing for an individual dog must be set by a veterinarian who has examined the animal.
How is GHK-Cu given to dogs?+
GHK-Cu is administered by subcutaneous injection or intramuscular injection or topical application. See the injection guide and reconstitution guide for handling detail.
What is the evidence for GHK-Cu in dogs?+
GHK-Cu is graded as emerging evidence on this site, drawing on 4 cited studies. GHK-Cu is a three-amino-acid peptide bound to copper, found naturally in blood plasma at levels that decline with age. Research describes it influencing the expression of several thousand genes involved in tissue remodelling, which is why it appears in both wound-healing and skin and coat contexts. The wound-healing evidence is genuinely strong, but it is rodent and human — no canine study exists, despite the frequently cited paper having appeared in a veterinary journal.
References
- 1.Canapp SO Jr, Farese JP, Schultz GS, et al. The effect of topical tripeptide-copper complex on healing of ischemic open wounds. Veterinary Surgery, 2003. PMID 14648529
- 2.Maquart FX, Bellon G, Chaqour B, et al. In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ in rat experimental wounds. Journal of Clinical Investigation, 1993. PMID 8227353
- 3.Pickart L, Vasquez-Soltero JM, Margolina A GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. BioMed Research International, 2015. PMID 26236730
- 4.Pickart L, Margolina A Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. International Journal of Molecular Sciences, 2018. PMID 29986520
Educational information — not veterinary medical advice
Everything on this page is compiled from published peer-reviewed literature for educational and research purposes. It does not establish a veterinarian-client-patient relationship (VCPR) and is not a substitute for veterinary examination and diagnosis. Most compounds described here are investigational or used off-label and are not FDA-approved for these purposes in dogs. Extralabel drug use in animals requires a valid VCPR and the direct supervision of a licensed veterinarian under AMDUCA (21 U.S.C. §360b). Dosing figures are reported as they appear in the source literature and are not recommendations.